Testing ACT001 in adults whose glioblastoma has come back
Original title: Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage study, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called ACT001 in adults whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary returned with a STAT3-high signature.
Who this trial is for. This trial is for adults whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has come back after standard treatment that included at least radiation therapy. Their tumor must have what doctors call a STAT3-high signature, and the trial is testing how well the drug ACT001 works for them.
Where it stands. The trial has not reported results. It is measuring how well ACT001 works in these patients. That answer is not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not care your own doctor can give you. If this sounds like your situation, you can ask your care team about it. They can help you look at whether a study like this makes sense for you.
What it doesn't mean: This does not mean ACT001 works. A trial is a test, not a proven treatment. Joining a study is not a promise that it will help you. It is not a cure, and no one can promise you a spot in it.
Source: ClinicalTrials.gov, September 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.